Table 1. Patient characteristics... | American Society of Hematology

Table 1.

Patient characteristics

Characteristics	AML15		AML17
Characteristics	Lestaurtinib	Control	Lestaurtinib	Placebo
Number randomized	88	87	212	113
Age group, years
0-15	0	0	3	2
16-29	9	10	22	10
30-39	15	14	20	10
40-49	24	26	57	31
50-59	30	28	83	44
60+	10	9	27	16
Median (range)	48 (16-66)	46 (16-65)	50 (5-68)	50 (6-65)
Sex
Female	47	51	113	57
Male	41	36	99	56
Type of disease
De novo	84	84	198	104
Secondary	3	4	10	6
High-risk MDS	0	0	4	3
Performance status*
0	54	51	127	64
1	30	31	69	38
2	3	2	10	6
3	1	3	5	4
4	0	0	0	0
WBC
0-9.9	17	25	48	29
10-49.9	33	37	100	42
50-99.9	19	10	31	20
100+	18	15	20	22
Median (range)	38.4 (0.2-363)	26.0 (1.2-308.0)	25.9 (0.8-360.0)	30.0 (0.8-285.8)
Cytogenetics
Favorable	5	6	11	5
Intermediate	64	69	190	97
Adverse	7	5	6	5
Unknown	12	7	5	6
Induction treatment
AML15
ADE	41	43
DA	43	40
FLAG-Ida	4	4
AML17
ADE†			38	21
ADE + GO3			17	9
ADE + GO6			26	13
DA + GO3			21	11
DA + GO6			26	14
DA60			41	24
DA90			44	21
SCT
Any	47	39	89	51
In 1st CR	33	29	46	25
Allograft	41	37	73	47
Allo in CR1	32	27	40	23
FLT3 mutation status
ITD alone	65	65	155	85
TKD alone	22	18	52	23
ITD+TKD	1	2	4	4
Not assessable	0	2	1	1
FLT3 ITD mutant percentage
<25%	18	22	55	31
25-50%	38	22	77	47
50%+	5	14	27	11
Unknown	5	9	0	0
Median	32.5	36.5	29.5	31
Range	5.8-92.5	3-98.4	5-98	3.5-96
NPM1c status
WT	42	34	83	52
Mutant	43	45	124	58
Not known	3	8	5	3

Characteristics	AML15		AML17
Characteristics	Lestaurtinib	Control	Lestaurtinib	Placebo
Number randomized	88	87	212	113
Age group, years
0-15	0	0	3	2
16-29	9	10	22	10
30-39	15	14	20	10
40-49	24	26	57	31
50-59	30	28	83	44
60+	10	9	27	16
Median (range)	48 (16-66)	46 (16-65)	50 (5-68)	50 (6-65)
Sex
Female	47	51	113	57
Male	41	36	99	56
Type of disease
De novo	84	84	198	104
Secondary	3	4	10	6
High-risk MDS	0	0	4	3
Performance status*
0	54	51	127	64
1	30	31	69	38
2	3	2	10	6
3	1	3	5	4
4	0	0	0	0
WBC
0-9.9	17	25	48	29
10-49.9	33	37	100	42
50-99.9	19	10	31	20
100+	18	15	20	22
Median (range)	38.4 (0.2-363)	26.0 (1.2-308.0)	25.9 (0.8-360.0)	30.0 (0.8-285.8)
Cytogenetics
Favorable	5	6	11	5
Intermediate	64	69	190	97
Adverse	7	5	6	5
Unknown	12	7	5	6
Induction treatment
AML15
ADE	41	43
DA	43	40
FLAG-Ida	4	4
AML17
ADE†			38	21
ADE + GO3			17	9
ADE + GO6			26	13
DA + GO3			21	11
DA + GO6			26	14
DA60			41	24
DA90			44	21
SCT
Any	47	39	89	51
In 1st CR	33	29	46	25
Allograft	41	37	73	47
Allo in CR1	32	27	40	23
FLT3 mutation status
ITD alone	65	65	155	85
TKD alone	22	18	52	23
ITD+TKD	1	2	4	4
Not assessable	0	2	1	1
FLT3 ITD mutant percentage
<25%	18	22	55	31
25-50%	38	22	77	47
50%+	5	14	27	11
Unknown	5	9	0	0
Median	32.5	36.5	29.5	31
Range	5.8-92.5	3-98.4	5-98	3.5-96
NPM1c status
WT	42	34	83	52
Mutant	43	45	124	58
Not known	3	8	5	3

NPM1c, nucelophosmin mutation; SCT, stem cell transplant; WBC, white blood cell count ×10⁹/L.

Two children did not complete the WHO performance status,

Includes people who were not eligible for GO in AML17 and 2 patients mistakenly originally believed to be APL.